<main class="html-publication" lang="en" role="main">
      

  <div class="publication-external">
    <ul class="organisation-logos">
        <li class="organisation-logos__logo">
          
<div class="gem-c-organisation-logo brand--department-of-health">
    <a class="gem-c-organisation-logo__container gem-c-organisation-logo__link gem-c-organisation-logo__crest gem-c-organisation-logo__crest--single-identity brand__border-color" href="/government/organisations/office-for-health-improvement-and-disparities">
      <span class="gem-c-organisation-logo__name">Office for Health<br>Improvement <br>&amp; Disparities</span>
</a>
</div>
        </li>
    </ul>
  </div>

  <header class="gem-c-inverse-header  gem-c-inverse-header--padding-top ">
    
  

<div class="gem-c-title gem-c-title--inverse govuk-!-margin-top-8 govuk-!-margin-bottom-0">
      <span class="govuk-caption-xl gem-c-title__context">
    Guidance
  </span>


  <h1 class="gem-c-title__text govuk-heading-xl">
    Advising men without symptoms of prostate disease who ask about the PSA test
  </h1>
</div>
  <p class="publication-header__last-changed">Updated 13 May 2022</p>

  </header>



<div class="govuk-grid-row sidebar-with-body" data-module="sticky-element-container">
    <div class="govuk-grid-column-one-quarter-from-desktop contents-list-container">
        <nav aria-label="Contents" class="gem-c-contents-list" data-module="gem-track-click" role="navigation">
    <h2 class="gem-c-contents-list__title">
      Contents
</h2>
    <ol class="gem-c-contents-list__list">
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 1" data-track-category="contentsClicked" data-track-label="#prostate-cancer" data-track-options="{&quot;dimension29&quot;:&quot;\n1. Prostate cancer&quot;}" href="#prostate-cancer"><span class="gem-c-contents-list__number">1. </span><span class="gem-c-contents-list__numbered-text">Prostate cancer</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 2" data-track-category="contentsClicked" data-track-label="#psa-test" data-track-options="{&quot;dimension29&quot;:&quot;\n2. \nPSA test&quot;}" href="#psa-test"><span class="gem-c-contents-list__number">2. </span><span class="gem-c-contents-list__numbered-text">PSA test</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 3" data-track-category="contentsClicked" data-track-label="#digital-rectal-examination-dre" data-track-options="{&quot;dimension29&quot;:&quot;\n3. Digital rectal examination (DRE)&quot;}" href="#digital-rectal-examination-dre"><span class="gem-c-contents-list__number">3. </span><span class="gem-c-contents-list__numbered-text">Digital rectal examination (DRE)</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 4" data-track-category="contentsClicked" data-track-label="#multiparametric-mri-mpmri" data-track-options="{&quot;dimension29&quot;:&quot;\n4. Multiparametric MRI (mpMRI)&quot;}" href="#multiparametric-mri-mpmri"><span class="gem-c-contents-list__number">4. </span><span class="gem-c-contents-list__numbered-text">Multiparametric MRI (mpMRI)</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 5" data-track-category="contentsClicked" data-track-label="#biopsy" data-track-options="{&quot;dimension29&quot;:&quot;\n5. Biopsy&quot;}" href="#biopsy"><span class="gem-c-contents-list__number">5. </span><span class="gem-c-contents-list__numbered-text">Biopsy</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 6" data-track-category="contentsClicked" data-track-label="#management-and-treatment" data-track-options="{&quot;dimension29&quot;:&quot;\n6. Management and treatment&quot;}" href="#management-and-treatment"><span class="gem-c-contents-list__number">6. </span><span class="gem-c-contents-list__numbered-text">Management and treatment</span></a>

        </li>
    </ol>
</nav>
      
<div class="gem-c-print-link govuk-!-display-none-print govuk-!-margin-top-0 govuk-!-margin-bottom-6">
    <button class="govuk-link govuk-body-s gem-c-print-link__button" data-module="print-link">Print this page</button>
</div>
    </div>

  <div class="print-wrapper">
    <div class="print-meta-data">
      <p>
  <img class="print-meta-data-licence" src="/assets/government-frontend/open-government-licence-min-93b6a51b518ff99714a1aa2a7d2162735c155ec3cb073c75fb88b2a332fa83d3.png">
</p>
<p>
  © Crown copyright 2022
</p>
<p>
  This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit <a href="https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3">nationalarchives.gov.uk/doc/open-government-licence/version/3</a> or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: <a href="mailto:psi@nationalarchives.gov.uk">psi@nationalarchives.gov.uk</a>.
</p>
<p>
  Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
</p>
<p>
  This publication is available at https://www.gov.uk/government/publications/prostate-specific-antigen-testing-explanation-and-implementation/advising-well-men-about-the-psa-test-for-prostate-cancer-information-for-gps
</p>


    </div>
  </div>

  <div class="main-content-container">
    <div class="gem-c-govspeak-html-publication">
  
<div class="gem-c-govspeak govuk-govspeak " data-module="govspeak">
    
    
      <div class="govspeak">
<p>This prostate cancer risk management programme (<abbr title="prostate cancer risk management programme">PCRMP</abbr>) information helps GPs give clear and balanced information to asymptomatic men who ask about prostate specific antigen (<abbr title="prostate specific antigen">PSA</abbr>) testing. The <abbr title="prostate specific antigen">PSA</abbr> test is available free to any man aged 50 and over who requests it.</p>

<p>GPs should use their clinical judgement to manage asymptomatic men and those aged under 50 who they consider to be at increased risk of prostate cancer.</p>

<p>GPs should follow <a class="govuk-link" href="https://www.nice.org.uk/guidance/ng12/chapter/Recommendations-organised-by-site-of-cancer#urological-cancers" rel="external">National Institute for Health and Care Excellence (<abbr title="National Institute for Health and Care Excellence">NICE</abbr>) guideline NG12</a> for the management of men who have symptoms of prostate disease.</p>

<h2>
<span class="number">1. </span>Prostate cancer</h2>

<p>Each year in the UK about 50,000 men are diagnosed with prostate cancer and about 12,000 die from the disease. See <a class="govuk-link" href="https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer" rel="external">Cancer Research UK prostate cancer statistics</a>.</p>

<p>Factors that increase the risk of prostate cancer include:</p>

<ul>
  <li>age – prostate cancer is rare under the age of 50 and risk increases with age</li>
  <li>family history – if you have a close relative, for example brother or father, who has had prostate cancer</li>
  <li>ethnicity – the lifetime risk is 1 in 4 for men of black ethnic origin compared to 1 in 8 for white men</li>
</ul>

<p>Prostate cancer is common and may not cause symptoms or shorten life. Some tested men may therefore face unnecessary diagnosis (overdiagnosis) of prostate cancer as well as associated anxiety, medical tests and treatments with side effects.</p>

<h2>
<span class="number">2. </span>
<abbr title="prostate specific antigen">PSA</abbr> test</h2>

<p>The prostate specific antigen (<abbr title="prostate specific antigen">PSA</abbr>) test is a blood test that can help diagnose prostate problems. <abbr title="prostate specific antigen">PSA</abbr> levels can be raised in a number of conditions, such as a urinary infection, an enlarged prostate, prostatitis or prostate cancer.</p>

<p>Most men have a <abbr title="prostate specific antigen">PSA</abbr> level less than 3ng/ml.</p>

<p>Around 75% (3 in 4) of men with raised <abbr title="prostate specific antigen">PSA</abbr> level (greater than or equal to 3ng/ml) will not have cancer.</p>

<p>A small proportion of men who have a low <abbr title="prostate specific antigen">PSA</abbr> level will later be found to have prostate cancer.</p>

<p>Before a <abbr title="prostate specific antigen">PSA</abbr> test, men should not have:</p>

<ul>
  <li>an active urinary infection or within previous 6 weeks</li>
  <li>ejaculated in previous 48 hours</li>
  <li>exercised vigorously, for example cycling in the previous 48 hours</li>
  <li>had a urological intervention such as prostate biopsy in previous 6 weeks</li>
</ul>

<p>When taking blood for <abbr title="prostate specific antigen">PSA</abbr> testing:</p>

<ul>
  <li>ensure the specimen will reach laboratory in time for the serum to be separated within 16 hours</li>
  <li>send samples to an ISO accredited laboratory</li>
  <li>repeat the test if not taken in ideal circumstances</li>
</ul>

<p>A <abbr title="prostate specific antigen">PSA</abbr> test will not distinguish between aggressive tumours (which are at an early stage but will develop quickly) and those which are not. Further tests may provide valuable information.</p>

<p>In the presence of symptoms of prostate disease, GPs should refer to <a class="govuk-link" href="https://www.nice.org.uk/guidance/ng12/chapter/Recommendations-organised-by-site-of-cancer#urological-cancers" rel="external"><abbr title="National Institute for Health and Care Excellence">NICE</abbr> guideline NG12</a>.</p>

<p>In the absence of symptoms, GPs should discuss the pros and cons of <abbr title="prostate specific antigen">PSA</abbr> tests with the patient. If a subsequent <abbr title="prostate specific antigen">PSA</abbr> test result shows raised <abbr title="prostate specific antigen">PSA</abbr> levels, the GP should use their clinical judgement to consider whether a referral is appropriate.</p>

<h3>
<span class="number">2.1 </span>
<abbr title="prostate specific antigen">PSA</abbr> testing and prostate cancer patient pathway</h3>

<figure class="image embedded"><div class="img"><img alt="" src="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/image_data/file/148179/PSA_test_consultation_flowchart_for_GP_info.drawio__1_.svg"></div></figure>

<h2>
<span class="number">3. </span>Digital rectal examination (<abbr title="digital rectal examination">DRE</abbr>)</h2>

<p><abbr title="digital rectal examination">DRE</abbr> allows assessment of the prostate for signs of prostate cancer (a hard gland, sometimes with palpable nodules) or benign enlargement (smooth, firm, enlarged gland). A gland that feels normal does not exclude a tumour.</p>

<p><a class="govuk-link" href="https://www.nice.org.uk/guidance/ng131" rel="external"><abbr title="National Institute for Health and Care Excellence">NICE</abbr> guideline NG131</a> suggests that the following investigations and treatments will be part of the onward diagnosis and management of your patient.</p>

<h2>
<span class="number">4. </span>Multiparametric MRI (<abbr title="multiparametric MRI">mpMRI</abbr>)</h2>

<p>Pre-biopsy <abbr title="multiparametric MRI">mpMRI</abbr> of the prostate gland aims to accurately locate clinically significant prostate cancer and facilitate targeted biopsy. Studies suggest that by using <abbr title="multiparametric MRI">mpMRI</abbr> prostate biopsy can be avoided by more than 25% of men and may reduce detection of clinically insignificant cancers.</p>

<h2>
<span class="number">5. </span>Biopsy</h2>

<p>A biopsy may confirm the diagnosis of prostate cancer and provide useful prognostic information. Techniques include transrectal ultrasound (<abbr title="transrectal ultrasound">TRUS</abbr>) and transperineal (<abbr title="transperineal biopsy">TP</abbr>) biopsies.</p>

<p>Most men experience blood in urine and semen after biopsy. About 2 out of 5 men describe a biopsy as painful. The most common complications are bleeding and infections including a small risk of sepsis. In this context, it is important for men considering the <abbr title="prostate specific antigen">PSA</abbr> test to understand the effects that biopsy can have on their quality of life.</p>

<p>Neither <abbr title="multiparametric MRI">mpMRI</abbr> nor prostate biopsy will detect all prostate cancers.</p>

<h2>
<span class="number">6. </span>Management and treatment</h2>

<p>Evidence about how best to treat localised prostate cancer is not clear in all cases.</p>

<p><a class="govuk-link" href="https://www.nice.org.uk/guidance/ng131" rel="external"><abbr title="National Institute for Health and Care Excellence">NICE</abbr> guideline NG131</a> includes recommendations about the treatment and management options for localised prostate cancer. The options include one or more of:</p>

<ul>
  <li>monitoring (surveillance)</li>
  <li>radical prostatectomy (open, laparoscopic or robotically assisted laparoscopic)</li>
  <li>targeted and external beam radiotherapy (<abbr title="external beam radiotherapy">EBRT</abbr>)</li>
  <li>brachytherapy (low and high dose rate)</li>
  <li>hormone therapy</li>
</ul>

<p>The options chosen will depend on a number of factors including the man’s general health and the stage of disease. Surgery and radiotherapy may offer the possibility of a cure but can have significant adverse effects on a man’s quality of life and wellbeing.</p>

<p>In this context it is important for men considering the <abbr title="prostate specific antigen">PSA</abbr> test to understand the effects that treatments may have on their quality of life, balanced against the risk of dying from prostate cancer.</p>

<h3>
<span class="number">6.1 </span>Information for well men aged 50 and over</h3>

<figure class="image embedded"><div class="img"><img alt="Infographic explaining PSA test. Outline of male body with labelled kidneys, bladder and prostate gland (which releases PSA molecules into the blood). Explanation of low (normal) and raised PSA level along with other reasons for raised levels." src="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/image_data/file/148180/PSA_test_explanation_infographic_new.svg"></div></figure>

<p>You can refer to the infographic above and direct patients to the <a class="govuk-link" href="https://www.gov.uk/government/publications/prostate-specific-antigen-testing-description-in-brief">information sheet for well men aged 50 and over</a> for a summary of the potential benefits and risks of <abbr title="prostate specific antigen">PSA</abbr> testing.</p>

<p>The information sheet for well men includes the above infographic, which explains the <abbr title="prostate specific antigen">PSA</abbr> test. It also includes a list of the potential advantages and disadvantages of the <abbr title="prostate specific antigen">PSA</abbr> test for men to consider when making a decision.</p>

<p>The Office for Health Improvement and Disparities created this information on behalf of the NHS.</p>

</div>


</div>
</div>
  </div>

  <div class="sticky-element" data-sticky-element="">
    <a class="govuk-link app-c-back-to-top dont-print" href="#contents">
    <svg class="app-c-back-to-top__icon" focusable="false" height="17" viewBox="0 0 13 17" width="13" xmlns="http://www.w3.org/2000/svg">
      <path d="M6.5 0L0 6.5 1.4 8l4-4v12.7h2V4l4.3 4L13 6.4z" fill="currentColor"></path>
    </svg>
    Contents
</a>

    <div class="sticky-element__print-link">
      
<div class="gem-c-print-link govuk-!-display-none-print govuk-!-margin-top-0 govuk-!-margin-bottom-6">
    <button class="govuk-link govuk-body-s gem-c-print-link__button" data-module="print-link">Print this page</button>
</div>
    </div>
  </div>
</div>

    </main>